Published in J Am Heart Assoc on January 02, 2014
The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond) (2016) 0.87
From bedside to bench-meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.80
Early activation of deleterious molecular pathways in the kidney in experimental heart failure with atrial remodeling. Physiol Rep (2017) 0.75
Innovative Therapeutics: Designer Natriuretic Peptides. JACC Basic Transl Sci (2016) 0.75
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med (2005) 6.50
Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA (2006) 4.30
Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev (2000) 4.10
Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet (2009) 3.81
Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation (2004) 3.56
Atrial natriuretic peptide elevation in congestive heart failure in the human. Science (1986) 3.37
Acute kidney injury and cardiovascular outcomes in acute severe hypertension. Circulation (2010) 2.76
Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail (2009) 2.72
Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet (2007) 2.48
SIMPLIFICATION OF THE ANTHRONE METHOD FOR THE DETERMINATION OF INULIN IN CLEARANCE STUDIES. J Lab Clin Med (1963) 2.19
Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol (2009) 2.06
Long-term effects of sildenafil in a rat model of chronic mitral regurgitation: benefits of ventricular remodeling and exercise capacity. Circulation (2012) 1.76
Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther (2009) 1.66
Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol (2012) 1.61
A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. J Am Coll Cardiol (2009) 1.53
Comparative effects of nesiritide and nitroglycerin on renal function, and incidence of renal injury by traditional and RIFLE criteria in acute heart failure. J Cardiovasc Pharmacol Ther (2011) 1.44
Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes. Circ Res (2010) 1.41
Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J (2008) 1.29
Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process. Proc Natl Acad Sci U S A (1986) 1.25
Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J (2006) 1.19
Differential effects of cGMP produced by soluble and particulate guanylyl cyclase on mouse ventricular myocytes. Exp Biol Med (Maywood) (2005) 1.07
A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation. J Biol Chem (2009) 1.01
Cardiovascular, renal, and endocrine response to atrial natriuretic peptide in angiotensin II mediated hypertension. Circ Res (1986) 1.01
Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury. J Am Soc Nephrol (2012) 1.01
Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol (2000) 0.99
High and low gain switches for regulation of cAMP efflux concentration: distinct roles for particulate GC- and soluble GC-cGMP-PDE3 signaling in rabbit atria. Circ Res (2004) 0.96
Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. J Am Coll Cardiol (2012) 0.95
Plasma arteriovenous cGMP difference as a useful indicator of nitrate tolerance in patients with heart failure. Circulation (1994) 0.92
The measurement of cyclic nucleotides by radioimmunoassay. Adv Biochem Psychopharmacol (1970) 0.91
Mechanical unloading versus neurohumoral stimulation on myocardial structure and endocrine function In vivo. Circulation (2000) 0.91
Intravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitations. J Cardiovasc Pharmacol Ther (2004) 0.89
Cardiorenal and neurohumoral function in a canine model of early left ventricular dysfunction. Circulation (1993) 0.87
Release of cyclic guanosine monophosphate evaluated as a diagnostic tool in cardiac diseases. Clin Chem (1991) 0.86
A direct microassay for aldosterone in plasma extracts. J Clin Endocrinol Metab (1978) 0.84
Clinical significance of urinary cyclic guanosine monophosphate in diagnosis of heart failure. Clin Chem (1994) 0.84
Acute heart failure associated with high admission blood pressure--a distinct vascular disorder? Eur J Heart Fail (2006) 0.84
Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol (2004) 0.84
A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. Hypertension (2010) 0.82
Renal vasodilatory effect of endothelial stimulation in patients with chronic congestive heart failure. J Am Coll Cardiol (1996) 0.81
On the relation of atrial natriuretic peptide and cyclic guanosine 3',5'-monophosphate plasma concentrations during ergometric exercise in healthy individuals. Horm Metab Res (1994) 0.80
Effects of a small bolus dose of ANF in healthy volunteers and in patients with volume retaining disorders. Klin Wochenschr (1990) 0.76
Low-dose atrial natriuretic factor and furosemide in experimental acute congestive heart failure. J Am Soc Nephrol (1993) 0.76
Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA (2003) 13.79
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell (2005) 5.71
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA (2007) 4.30
Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol (2002) 3.68
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA (2008) 3.31
Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA (2011) 2.86
Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension (2007) 2.77
Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res (2002) 2.51
Limitations of estimating glomerular filtration rate from serum creatinine in the general population. Mayo Clin Proc (2006) 2.37
The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol (2010) 2.37
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol (2008) 2.35
Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int (2004) 2.19
Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med (2008) 2.14
Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol (2008) 2.04
Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation (2002) 2.02
Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol (2006) 1.98
Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail (2008) 1.89
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J (2011) 1.88
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A (2005) 1.85
Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension (2007) 1.84
Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation (2004) 1.82
Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction. J Am Coll Cardiol (2011) 1.78
The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide. Hypertension (2010) 1.74
Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation (2007) 1.72
Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation (2007) 1.69
Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation (2004) 1.67
Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol (2012) 1.66
BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail (2004) 1.66
Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol (2012) 1.61
Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. J Am Coll Cardiol (2011) 1.59
A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. J Am Coll Cardiol (2009) 1.53
Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension (2006) 1.52
Mineralocorticoid escape by the kidney but not the heart in experimental asymptomatic left ventricular dysfunction. Hypertension (2007) 1.50
Participation bias in a population-based echocardiography study. Ann Epidemiol (2004) 1.48
Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J (2009) 1.47
Natriuretic peptides and therapeutic applications. Heart Fail Rev (2007) 1.44
Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention. Circulation (2003) 1.44
The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol (2010) 1.43
Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network. J Card Fail (2012) 1.43
Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. J Hypertens (2003) 1.42
Biology of the natriuretic peptides. Am J Cardiol (2008) 1.41
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail (2005) 1.39
Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation (2007) 1.34
Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation (2011) 1.33
Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol (2006) 1.31
Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J (2013) 1.30
HIV promoter integration site primarily modulates transcriptional burst size rather than frequency. PLoS Comput Biol (2010) 1.30
B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation (2005) 1.28
Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients. J Am Soc Nephrol (2004) 1.27
Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int (2002) 1.27
Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure. Circulation (2005) 1.27
The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol (2004) 1.27
Membrane guanylyl cyclase receptors: an update. Trends Endocrinol Metab (2006) 1.27
Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol (2006) 1.25
Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail (2004) 1.24
Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J (2012) 1.24
Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection. Am J Physiol Regul Integr Comp Physiol (2011) 1.24
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J (2012) 1.24
Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail (2011) 1.24
Coupling of a vented column with splitless nanoRPLC-ESI-MS for the improved separation and detection of brain natriuretic peptide-32 and its proteolytic peptides. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.23
Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol (2007) 1.23
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol (2005) 1.23
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel) (2013) 1.21
Changes in diastolic dysfunction in diabetes mellitus over time. Am J Cardiol (2009) 1.21
Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int (2002) 1.20
A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol (2011) 1.20